Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)

Annals of Surgery

Volumn 255, Issue 3, 2012, Pages 534-539

  Sorbye, Halfdan ^a   Mauer, Murielle ^b   Gruenberger, Thomas ^c   Glimelius, Bengt ^d,e   Poston, Graeme J ^f   Schlag, Peter M ^g   Rougier, Philippe ^h   Bechstein, Wolf O ⁱ   Primrose, John N ^j   Walpole, Euan T ^k   Finch Jones, Meg ^l   Jaeck, Daniel ^m   Mirza, Darius ⁿ   Parks, Rowan W ^o   Collette, Laurence ^e   Van Cutsem, Eric ^p   Scheithauer, Werner ^q   Lutz, Manfred P ^r   Nordlinger, Bernard ^g  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b EORTC DATA CENTER   (Belgium)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UPPSALA UNIVERSITY   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^g HUMBOLDT UNIVERSITY   (Germany)

^h HÔPITAL AMBROISE PARÉ   (France)

ⁱ UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^j SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^k UNIVERSITY OF QUEENSLAND   (Australia)

^l BRISTOL ROYAL INFIRMARY   (United Kingdom)

^m HÔPITAL DE HAUTEPIERRE   (France)

ⁿ UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^o ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^p UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^q Comprehensive Cancer Center ^*  (Germany)

^r Caritasklinik St Theresa   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ARTICLE; BODY MASS; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; LIVER INJURY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PERIOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84857649652     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182456aa2     Document Type: Article

References (29)

1. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer. 1996;77:1254-1262.
2. Tomlinson JS, Jarnagin WR, De Matteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25:4575-4580.
3. Charnsangavej C, Clary B, Fong Y, et al. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13:1261-1268.
4. Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125-135.
5. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-318.
6. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109-3116.
7. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198-2204.
8. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007-1016.
9. Mitry E, Fields ALA, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008;26:4906-4911.
10. Parks R, Gonen M, Kemeny N, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg. 2007;204:753-761.
11. Power DG, Kemeny NE. Role of adjuvant therapy after resection of colorectal cancer liver metastases. J Clin Oncol. 2010;28:2300-2309.
12. NCCN practice guidelines in oncology-Colon Cancer v2. 2010. http://www.nccn.org. Access date August 1 2010.
13. Nordlinger B, Van Cutsem E, Gruenberger T, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009;20:985-992.
14. Adam R, Aloia T, Figueras J, et al. LiversMetSurvey: analysis of clinicopathologic factors associated with the efficacy of preoperative chemotherapy in 2, 122 patients with colorectal liver metastases [ASCO Annual Meeting Proceedings Part I]. J Clin Oncol. 2006;24:18s (suppl; abstr 3521).
15. Adam R, Bhangui P, Poston G, et al. Is perioperative chemotherapy useful for solitary metachronous, colorectal liver metastases? Ann Surg. 2010;252:774-785
16. Oussoultzoglou E, Rosso E, Fuchshuber P, et al. Perioperative carcinoembryonic antigen measurements to predict curability after liver resection for colorectal metastases. Arch Surg. 2008;143:1150-1158.
17. Benson AB, Schrag D, Somerfield MR, et al. American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408-3419.
18. Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27:1829-1835.
19. Sorbye H, Köhne CH, Sargent DJ, et al. Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. Ann Oncol. 2008;18:1666-1672.
20. Tampellini M, Saini A, Alabiso I, et al. The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients. Br J Cancer. 2006;95:13-20.
21. Fernandez FG, Ritter J, Goodwin JW. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005;200:845-853.
22. Dignam JJ, Polite BN, Yothers G, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006;98:1647-1654.
23. Reddy SK, Zorzi D, Lum YW, et al. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multiinstitutional analysis. Ann Surg Oncol. 2009;16:1809-1819.
24. Collett D. Modelling Survival Data in Medical Research. London, Great Britain: Chapman & Hall; 1994:78-81
25. Sauerbrei W, Schumacher M. A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med. 1992;11:2093-2109.
26. Strimakos AS, Cunningham D, Mikropoulos C, et al. The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. Ann Oncol. 2010;21:1013-1019.
27. Bird NC, Mangnall D, Majeed AW. Biology of colorectal liver metastases: a review. J Surg Oncol. 2006;94:68-80.
28. Pachos KA, Canovas D, Bird NC. The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cellular Signaling. 2009;21:665-674.
29. Li Y, Cao H, Jiao C, et al. Carcinoembryonic antigen interacts with TGF-β receptor and inhibits TGF-β signaling in colorectal cancers. Cancer Res. 2010;70:8159-8168.